Aim: To evaluate the efficacy and safety of transurethral application of alprostadil (MUSE^(R) ) for the treatment oferectile dysfunction in Indonesians. Methods: Twenty erectile dysfunction patients aged between 32-7...Aim: To evaluate the efficacy and safety of transurethral application of alprostadil (MUSE^(R) ) for the treatment oferectile dysfunction in Indonesians. Methods: Twenty erectile dysfunction patients aged between 32-74 years oldwere recruited in this study. The inclusion criteria were as follows: 1) adult males 18 years or older with a subjectivecomplaint or erectile dysfunction, 2) to provide written informed consent, 3) to agree not to use other forms of treat-ment for erectile dysfunction, 4) fulfill the screening laboratory values. Part Ⅰ, eligible patients were titrated in theclinic starting with a dose of 250μg and proceed in a stepwise manner to 500 μg and 1000 μg on separate clinic visitsuntil they identified a dose that produced a satisfactory response. The interval between each in-clinic titration was 2-3days. Each in-clinic titration dose was evaluated at 15 rain intervals over a one hour period for erection assessment,blood pressure and pulse. Part 2, patients used MUSE at home for three months at the dose identified during the in-clinic titration. Monthly interim visits were required for patient follow-up and drug distribution. At the end of thestudy, patients had another laboratory (except testosterone, only assayed in screening procedure) and physical examina-tion. Results: The etiology of erectile dysfunction was psychological in 5 patients and organic in 15 patients. The65% of the patients achieved the erection scale of 4 or 5 either in the clinic or at home, 10% achieved the scale of 4at home, but not in the clinic, and 25% only achieved the scale of 2 or 3 with the highest dose of 1000 μg either in theclinic or at home. No significant differences were found in biochemical examination before and after the study. The60% of the patients who achieved erection scale 4 or 5 continued to use MUSE until the end of the study, while 40%of them complained of pain at the time of MUSE application, during erection and/or during intercourse. They withdrewfrom the study. Conclusion: Transurethral application of alprostadil (MUSE) is effective and safe to produce erec-tion sufficient for intercourse in erectile dysfunction of various etiologies. Pain during application, erection and inter-course is a common side effect and a cause of withdrawal.展开更多
文摘Aim: To evaluate the efficacy and safety of transurethral application of alprostadil (MUSE^(R) ) for the treatment oferectile dysfunction in Indonesians. Methods: Twenty erectile dysfunction patients aged between 32-74 years oldwere recruited in this study. The inclusion criteria were as follows: 1) adult males 18 years or older with a subjectivecomplaint or erectile dysfunction, 2) to provide written informed consent, 3) to agree not to use other forms of treat-ment for erectile dysfunction, 4) fulfill the screening laboratory values. Part Ⅰ, eligible patients were titrated in theclinic starting with a dose of 250μg and proceed in a stepwise manner to 500 μg and 1000 μg on separate clinic visitsuntil they identified a dose that produced a satisfactory response. The interval between each in-clinic titration was 2-3days. Each in-clinic titration dose was evaluated at 15 rain intervals over a one hour period for erection assessment,blood pressure and pulse. Part 2, patients used MUSE at home for three months at the dose identified during the in-clinic titration. Monthly interim visits were required for patient follow-up and drug distribution. At the end of thestudy, patients had another laboratory (except testosterone, only assayed in screening procedure) and physical examina-tion. Results: The etiology of erectile dysfunction was psychological in 5 patients and organic in 15 patients. The65% of the patients achieved the erection scale of 4 or 5 either in the clinic or at home, 10% achieved the scale of 4at home, but not in the clinic, and 25% only achieved the scale of 2 or 3 with the highest dose of 1000 μg either in theclinic or at home. No significant differences were found in biochemical examination before and after the study. The60% of the patients who achieved erection scale 4 or 5 continued to use MUSE until the end of the study, while 40%of them complained of pain at the time of MUSE application, during erection and/or during intercourse. They withdrewfrom the study. Conclusion: Transurethral application of alprostadil (MUSE) is effective and safe to produce erec-tion sufficient for intercourse in erectile dysfunction of various etiologies. Pain during application, erection and inter-course is a common side effect and a cause of withdrawal.
